2024
Artificial Intelligence Predicts Hospitalization for Acute Heart Failure Exacerbation in Patients Undergoing Myocardial Perfusion Imaging
Feher A, Bednarski B, Miller R, Shanbhag A, Lemley M, Miras L, Sinusas A, Miller E, Slomka P. Artificial Intelligence Predicts Hospitalization for Acute Heart Failure Exacerbation in Patients Undergoing Myocardial Perfusion Imaging. Journal Of Nuclear Medicine 2024, 65: jnumed.123.266761. PMID: 38548351, PMCID: PMC11064832, DOI: 10.2967/jnumed.123.266761.Peer-Reviewed Original ResearchConceptsMyocardial perfusion imagingHF hospitalizationHeart failureStress left ventricular ejection fractionPerfusion imagingHF exacerbationPredictive of HF hospitalizationsSPECT/CT myocardial perfusion imagingMyocardial perfusionInternational cohortAcute heart failure exacerbationMedian follow-upVentricular ejection fractionReceiver-operating-characteristic curveClinical risk factorsHeart failure exacerbationExternal validation cohortAcute HF exacerbationPrevent HF hospitalizationsImaging parametersCalcium scoreEjection fractionClinical parametersCT scanValidation cohort
2023
Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study
Madhani A, Sabogal N, Massillon D, Paul L, Rodriguez C, Fine D, Helmke S, Winburn M, Kurian D, Raiszadeh F, Teruya S, Cohn E, Einstein A, Miller E, Connors L, Maurer M, Ruberg F. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. Journal Of The American Heart Association 2023, 12: e028973. PMID: 37486082, PMCID: PMC10492994, DOI: 10.1161/jaha.122.028973.Peer-Reviewed Original ResearchConceptsATTR-CMHeart failurePrealbumin concentrationsLeft ventricular wall thicknessPhenotypic penetranceHereditary ATTR-CMOlder black patientsAdvanced heart failureV122I variantVentricular wall thicknessProspective multisite studyYears of ageBlack individualsPyrophosphate imagingEchocardiographic parametersUnderdiagnosed causeBlack patientsSelf-identified Black individualsHF controlsClinical penetrancePrevalenceHispanic individualsMultisite studyBlack participantsPatientsDesign and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study
Ruberg F, Blaner W, Chiuzan C, Connors L, Einstein A, Fine D, Helmke S, Kurian D, Pandey S, Raiszadeh F, Rodriguez C, Sabogal N, Teruya S, Winburn M, Chung W, Cohn E, Miller E, Kelly J, Maurer M. Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. Journal Of The American Heart Association 2023, 12: e028534. PMID: 37066788, PMCID: PMC10227254, DOI: 10.1161/jaha.122.028534.Peer-Reviewed Original ResearchConceptsATTR-CMHeart failureHealth/National HeartOlder black patientsYears of ageCaribbean Hispanic patientsDeposition of transthyretinNoninvasive nuclear imagingBlack patientsHispanic patientsProspective studyBlood InstituteSelf-identified Black individualsNational HeartCardiac amyloidosisUS FoodImportant causeSecondary objectiveOlder individualsSubstitution of valineHispanic individualsNuclear imagingNational InstituteBlack individualsPatients
2021
Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy
Higgins AY, Annapureddy AR, Wang Y, Minges KE, Bellumkonda L, Lampert R, Rosenfeld LE, Jacoby DL, Curtis JP, Miller EJ, Freeman JV. Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy. American Heart Journal 2021, 246: 21-31. PMID: 34968442, DOI: 10.1016/j.ahj.2021.12.011.Peer-Reviewed Original ResearchConceptsNon-ischemic cardiomyopathyAtrial fibrillation/flutterChronic lung diseaseCardiac sarcoidosisHeart failureCS patientsNICM patientsICD implantationLung diseaseNew York Heart Association class III heart failureNational Cardiovascular Data Registry ICD RegistryNYHA class IV heart failureClass III heart failureClass IV heart failureImplantable cardioverter defibrillator implantationKaplan-Meier survival curvesCox proportional hazards modelPredictors of mortalityCardioverter-defibrillator implantationVentricular ejection fractionMultivariable logistic regressionPrior ventricular arrhythmiasProportional hazards modelRate of deathTime of implantation
2016
Can 99mTc-Pyrophosphate Aid in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis?
Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL. Can 99mTc-Pyrophosphate Aid in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis? JACC Cardiovascular Imaging 2016, 10: 713-714. PMID: 27568122, PMCID: PMC5318295, DOI: 10.1016/j.jcmg.2016.06.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAmyloid Neuropathies, FamilialAsymptomatic DiseasesCardiomyopathiesDisease ProgressionEarly DiagnosisFemaleGenetic Predisposition to DiseaseHeart FailureHumansMaleMiddle AgedMutationPhenotypePrealbuminPredictive Value of TestsRadionuclide ImagingRadiopharmaceuticalsTechnetium Tc 99m Pyrophosphate